The pharmaceutical industry stands at an inflection point defined by one of the largest drug pipelines in human history. Although 2026 has been characterized by a slight reduction in the overall pipeline asset number, reality remains that the 2026 pipeline is nearly 70% larger than it was 10 years ago. (Citeline Phama R&D Annual Review 2026) The pipeline continues to be dominated by injectable biologic molecules such as Monoclonal antibodies (mAbs), Antibody-Drug Conjugates (ADCs) and Oligonucleotides and RNA Therapeutics (TIDES). Another unique aspect of the current drug pipeline is the percentage of assets owned by emerging companies vs. traditional large-molecule incumbents and Big Pharma. When you combine these scenarios with the impact of global homecare initiatives and a biologic injectable patent cliff valued at hundreds of billions of dollars, it becomes quite clear that there will be a continued need for innovative Prefillable Syringe (PFS) and Autoinjector (AI) solutions that can expedite biologic drug approvals and ultimately support delivery to a global patient population.
Biologics now represent a substantial and growing share of the late-stage pipeline molecules. Additionally, the late-stage pipeline features thousands of new modality candidates, with mAb’s remaining the largest category and expanding beyond legacy oncology and immunology areas and moving into neurology, rare disease and cardiovascular indications. Emerging biotech firms originate a disproportionate share of these molecules, often advancing novel targets and formats that large pharma later acquire or partners. The implication is clear: many of these assets will require subcutaneous self-administration delivery formats like PFS and AI’s to reach broad populations, especially for chronic conditions managed outside the hospital.
These pipeline characteristics coincide with a structural acceleration of homecare. Patients and payers increasingly demand therapies that can be administered outside infusion centers. PFS and AI’s, especially when you consider the holistic patient population linked with GLPs, have truly changed the game. PFS and AI have become the preferred drug delivery format to support self-injection of biologics for many reasons we know or have personally experienced at this point in our daily lives including reduction in preparation steps, minimizing medication errors, improved adherence and lower total cost of care. Between the COVID-era normalization of decentralized care and the explosion of GLP-1s, homecare is no longer a convenience, it’s a foundational aspect that supports maximum market-access for many therapeutics.
Against all of this backdrop, the biologics patent cliff is reshaping competitive dynamics as well. Over the next decade, more than 100 U.S. biologics are expected to lose exclusivity, representing hundreds of billions of dollars in potential biosimilar opportunities.( Assessing the Biosimilar Void in the U.S. | IQVIA) In this space, originators of biosimilars are faced with a reality that launching in a vial format first probably won’t make sense for any therapeutic area that is already serviced by a PFS/AI/homecare model. This urgency to launch in a PFS / AI combination product continues to create opportunities for integrated solutions and other technology differentiators, all geared towards enabling drugs to come to market faster and improve the overall patient experience.
The resultant pressures mentioned above open the door for integrated solution innovation that empowers expertise and capabilities from across the industry supply chain to support the need to get drugs into the hands of patients across the globe as efficiently as possible. This is why solutions like West Synchrony® S1 prefillable syringe system and Ypsomed Clear to Clinic® can provide accelerator platforms for industry to lean on and bring innovative drugs to life faster and with fewer resources. By providing verified systems and clinic-ready solutions, industry has the unique capacity to leverage data and documentation from across the supply chain to reduce the overall need for early-stage evaluation, various bridging studies and essentially gain back a considerable amount of time, money and effort.
In summary, one of the largest pipelines in history, the migration of care into the home and the biologic patent cliff converge on a single operational imperative: PFS / AI combination product excellence from day one of product drug launches. Integrated solutions such as West Synchrony and Ypsomed Clear to Clinic lower the technical and regulatory barriers that once made the journey to a PFS / AI product launch challenging enough that companies devoted these efforts to Life Cycle Management. However, those that adopt these platforms will not only bring innovative biologics to patients faster but will also expand access and establish durable competitive positions in a market that rewards speed and patient centric solutions.
.png "Rational Based Drug Design Summit Europe Returns to Amsterdam in January 2027"){kind=icon}
